Neurocrine Biosciences (NBIX) vs Twist Bioscience (TWST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Twist Bioscience (TWST) has outperformed Neurocrine Biosciences (NBIX) over the past year, gaining 400.2% versus a gain of 4.7%. Over five years, TWST leads with a +38.0% price change compared with +37.2% for NBIX. Neurocrine Biosciences is the larger company by market cap ($14.35 billion vs $9.94 billion), about 1.4 times the size.
Neurocrine Biosciences converts more of its revenue into profit, with a net margin of 16.7% versus -20.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NBIX | TWST |
|---|---|---|
| Share price | $141.15 | $149.88 |
| Market cap | $14.35B | $9.94B |
| 1-day change | -1.62% | -3.71% |
| YTD return | +1.16% | +390.70% |
| 1-year return | +4.72% | +400.16% |
| 5-year return | +37.24% | +37.99% |
| P/E ratio (TTM) | 20.70 | — |
| Forward P/E | 11.88 | — |
| EPS (TTM) | $6.82 | $-2.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.86B | $376.57M |
| Revenue growth (YoY) | +21.45% | +20.32% |
| Net income (latest FY) | $478.60M | $-77.67M |
| Gross margin | 98.18% | 50.72% |
| Operating margin | 21.64% | -36.18% |
| Net margin | 16.73% | -20.63% |
| 52-week high | $186.12 | $219.71 |
| 52-week low | $122.14 | $23.30 |
| Distance from 52-week high | -24.16% | -31.78% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +46.86% | -10.76% |
| Average volume | 1.30M | 1.99M |
| Shares outstanding | 101.65M | 66.30M |
| Employees | 2,500 | 979 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TWST has outperformed NBIX by 395.4 percentage points over the past year.
- Neurocrine Biosciences is more profitable, keeping 16.7 cents of every revenue dollar as net income versus -20.6 cents for Twist Bioscience.
About Neurocrine Biosciences
NBIX stock →Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,500 employees
About Twist Bioscience
TWST stock →Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 979 employees
NBIX vs TWST FAQ
Which is bigger, Neurocrine Biosciences or Twist Bioscience?
Neurocrine Biosciences (NBIX) is larger, with a market capitalization of $14.35B compared with $9.94B for Twist Bioscience (TWST).
Which stock has performed better over the past year, NBIX or TWST?
TWST returned +400.16% over the past 12 months, compared with +4.72% for NBIX (price return, excluding dividends). Past performance does not predict future results.
Are Neurocrine Biosciences and Twist Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.